KaliVir Immunotherapeutics
Develops oncolytic immunotherapies for patients with advanced solid tumors
$14MSeries A
Role not disclosedSI
SV Investment
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $74M 2 disclosed · full round size, not this investor’s share